|
< back to headlines
August 1, 2007
Aegerion Pharmaceuticals, Inc. Hires Vice President, General
Counsel And Secretary
BRIDEGWATER, NJ (August 1, 2007) – Aegerion Pharmaceuticals,
Inc. announced that Christine Pellizzari has joined the
company as its Vice President, General Counsel and
Secretary. Ms. Pellizzari will be responsible for
directing the legal activities of the company, reporting
directly to the President and CEO.
Prior to joining Aegerion, Ms. Pellizzari served as Senior
Vice President, General Counsel and Secretary of Dendrite
International, Inc., a provider of sales effectiveness,
promotional and compliance solutions to the global
pharmaceutical industry. Ms. Pellizzari joined
Dendrite in 1998 and served as its General Counsel from 2000
to 2007. During her tenure, Ms. Pellizzari built and
managed the company’s global legal organization and was
responsible for legal, compliance and corporate secretarial
functions worldwide. She was a member of the company's
Executive Operations Management Committee and helped lead
many critical initiatives, including the sale of the company
to Cegedim S.A. in May, 2007.
Ms. Pellizzari joined Dendrite from the law firm of Wilentz,
Goldman & Spitzer where she specialized in healthcare
transactions. Before joining Wilentz, Ms. Pellizzari
served as law clerk to the Honorable Reginald Stanton,
Assignment Judge, Morris/Sussex Vicinage, Superior Court of
New Jersey from 1994 to 1995. Ms. Pellizzari received
her Bachelor of Arts degree from the University of
Massachusetts in Amherst, MA and her Juris Doctorate from
the University of Colorado, School of Law in Boulder, CO
"We are extremely pleased that someone with Christine
Pellizzari’s considerable experience in areas ranging from
corporate governance and securities regulation to licensing
arrangements and international corporate transactions will
be overseeing our legal function. Her appointment rounds out
our executive leadership team and her public company
expertise should be particularly valuable to us in the
months and years ahead,” said Jerry Wisler, President and
CEO of Aegerion Pharmaceuticals.
“I am delighted to have joined Aegerion,” said Ms.
Pellizzari. “My new colleagues are all top tier in
their respective areas of focus. I believe my skills
will be complementary and I look forward to working with
such a highly qualified and dedicated leadership team.”
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. is a privately held specialty
pharmaceutical company focused on the development and
commercialization of promising pharmaceuticals to treat
cardiovascular and metabolic disease. The Company's initial
focus will be on hyperlipidemia. Its most advanced products
have demonstrated significant LDL lowering activity in human
trials and are currently in Phase II testing.
Contact
Kate Childress,
Vox Medica Health-care Public Relations Group
(t): 215-238-8500 x 1107
(e):
kchildress@voxmedica.com
###
|
 |
